About Channavix Therapeutics

Channavix Therapeutics is developing a portfolio of non-addictive, non-opioid analgesics that utilize local delivery mechanisms to provide multi-week pain relief for acute and chronic conditions in both human and veterinary markets. Their innovative programs target pain signaling through NaV1.8 inhibition and neuropeptide release modulation, effectively reducing pain without the risks associated with traditional opioid treatments.

```xml <problem> Current opioid-based pain management solutions carry a high risk of addiction and systemic side effects. Existing non-opioid analgesics often lack the efficacy or duration needed to provide adequate relief for acute and chronic pain conditions. </problem> <solution> Channavix Therapeutics is developing a portfolio of non-addictive, non-opioid analgesics designed for localized delivery and multi-week pain relief. Their therapeutic programs target pain signaling through two distinct mechanisms: NaV1.8 inhibition and neuropeptide release modulation. By focusing on local administration and genetically validated targets, Channavix aims to reduce pain effectively without the risks associated with traditional opioid treatments or systemic exposure. These programs are being developed for both human and veterinary markets, addressing a range of pain conditions. </solution> <features> - NaV1.8 Inhibition Program: Inhibits NaV1.8 – Magi1 binding, a scaffolding protein involved in anchoring the NaV1.8 ion channel at the cell surface. - AP2 Program: Inhibits neurons from releasing neuropeptides (e.g., CGRP & Substance P) in response to pain stimuli. - Local delivery mechanisms for targeted pain relief. - Multi-week analgesia demonstrated _in vivo_. - Non-addictive formulations. - Patented and patent-pending technology. - Programs target genetically validated targets. - No observed neurotoxicity. </features> <target_audience> The primary target audience includes human patients and veterinary subjects suffering from acute, neuropathic, and chronic pain conditions, such as post-surgical pain and osteoarthritis. </target_audience> ```

What does Channavix Therapeutics do?

Where is Channavix Therapeutics located?

Channavix Therapeutics is based in Itá, United States.

When was Channavix Therapeutics founded?

Channavix Therapeutics was founded in 2022.

Location

Itá, United States

Founded

2022

Employees

3 employees

Looking for specific startups?

Try our free semantic startup search

Channavix Therapeutics

Score: 19/100

AI-Generated Company Overview (experimental) – could contain errors

Executive Summary

channavix.com 100+

Founded 2022 – Itá, United States

Funding

No funding information available. Click "Fetch funding" to run a targeted funding scan.

Team (<5)

No team information available. Click "Fetch founders" to run a focused founder search.

Company Description

Problem

Current opioid-based pain management solutions carry a high risk of addiction and systemic side effects. Existing non-opioid analgesics often lack the efficacy or duration needed to provide adequate relief for acute and chronic pain conditions.

Solution

Channavix Therapeutics is developing a portfolio of non-addictive, non-opioid analgesics designed for localized delivery and multi-week pain relief. Their therapeutic programs target pain signaling through two distinct mechanisms: NaV1.8 inhibition and neuropeptide release modulation. By focusing on local administration and genetically validated targets, Channavix aims to reduce pain effectively without the risks associated with traditional opioid treatments or systemic exposure. These programs are being developed for both human and veterinary markets, addressing a range of pain conditions.

Features

NaV1.8 Inhibition Program: Inhibits NaV1.8 – Magi1 binding, a scaffolding protein involved in anchoring the NaV1.8 ion channel at the cell surface.

AP2 Program: Inhibits neurons from releasing neuropeptides (e.g., CGRP & Substance P) in response to pain stimuli.

Local delivery mechanisms for targeted pain relief.

Multi-week analgesia demonstrated _in vivo_.

Non-addictive formulations.

Patented and patent-pending technology.

Programs target genetically validated targets.

No observed neurotoxicity.

Target Audience

The primary target audience includes human patients and veterinary subjects suffering from acute, neuropathic, and chronic pain conditions, such as post-surgical pain and osteoarthritis.